The blockade of immune checkpoint receptors has made great strides in the treatment of
major cancers, including melanoma, Hodgkin's lymphoma, renal, and lung cancer. However …

In contrast to most other malignancies, hepatocellular carcinoma (HCC), which accounts for
approximately 90% of primary liver cancers, arises almost exclusively in the setting of …

Immunotherapy has gained increasing focus in treating pancreatic ductal adenocarcinoma
(PDAC), since conventional therapies like chemotherapy could not provide satisfactory …

Interactions between immune and malignant cells have been known to have clinical
relevance for decades. The potential for immune control is now being therapeutically …

Background and aims Chronic inflammation induced by chronic hepatitis B virus (HBV)
infection increases the risk of hepatocellular carcinoma (HCC). However, little is known …

Primary liver cancer (PLC) is one of the most common malignancies in China, where it ranks
second in mortality and fifth in morbidity. Currently, liver transplantation, hepatic tumor …

Background Fibrinogen-like protein 1 (FGL1)—Lymphocyte activating gene 3 (LAG-3)
pathway is a promising immunotherapeutic target and has synergistic effect with …

Background & Aims Ligand binding to inhibitory receptors on immune cells, such as
programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4) …

Introduction: Although immune checkpoint inhibitors (ICIs) have been considered as
promising agents for the treatment of advanced hepatocellular carcinoma (HCC), previous …

Hepatocellular carcinoma (HCC) is the most common malignancy worldwide, and is
especially common in China. A total of 70%–80% of patients are diagnosed at an advanced …